 BOSTON--BUSINESS WIRE--Astria Therapeutics, Inc. NASDAQ:ATXS, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema HAE, today announced that it will share new preclinical data for STAR-0215 in a presentation titled STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE at the 2022 American Academy of Allergy, Asthma and Immunology AAAI Annual Scientific Meeting in Phoenix, Arizona. The post 